Literature DB >> 14661957

Phosphorylation and mutation of human cardiac troponin I deferentially destabilize the interaction of the functional regions of troponin I with troponin C.

Monica X Li1, Xu Wang, Darrin A Lindhout, Nina Buscemi, Jennifer E Van Eyk, Brian D Sykes.   

Abstract

We have utilized 2D [(1)H,(15)N]HSQC NMR spectroscopy to elucidate the binding of three segments of cTnI in native, phosphorylated, and mutated states to cTnC. The near N-terminal region (cRp; residues 34-71) contains the protein kinase C (PKC) phosphorylation sites S41 and S43, the inhibitory region (cIp; residues 128-147) contains another PKC site T142 and a familial hypertrophic cardiomyopathy (FHC) mutation R144G, and the switch region (cSp; residues 147-163) contains the novel p21-activated kinase (PAK) site S149 and another FHC mutation R161W. While S41/S43 phosphorylation of cRp had minimal disruption in the interaction of cRp and cTnC.3Ca(2+), T142 phosphorylation reduced the affinity of cIp for cCTnC.2Ca(2+) by approximately 14-fold and S149 phosphorylation reduced the affinity of cSp for cNTnC.Ca(2+) by approximately 10-fold. The mutation R144G caused an approximately 6-fold affinity decrease of cIp for cCTnC.2Ca(2+) and mutation R161W destabilized the interaction of cSp and cNTnC.Ca(2+) by approximately 1.4-fold. When cIp was both T142 phosphorylated and R144G mutated, its affinity for cCTnC.2Ca(2+) was reduced approximately 19-fold, and when cSp was both S149 phosphorylated and R161W mutated, its affinity for cNTnC.Ca(2+) was reduced approximately 4-fold. Thus, while the FHC mutation R144G enhances the effect of T142 phosphorylation on the interaction of cIp and cCTnC.2Ca(2+), the FHC mutation R161W suppresses the effect of S149 phosphorylation on the interaction of cSp and cNTnC.Ca(2+), demonstrating linkages between the FHC mutation and phosphorylation of cTnI. The observed alterations corroborate well with structural data. These results suggest that while the modifications in the cRp region have minimal influence, those in the key functional cIp-cSp region have a pronounced effect on the interaction of cTnI and cTnC, which may correlate with the altered myofilament function and cardiac muscle contraction under pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661957     DOI: 10.1021/bi035408y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C.

Authors:  Nicholas Swindle; Svetlana B Tikunova
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

2.  AMP-activated protein kinase phosphorylates cardiac troponin I at Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent function.

Authors:  Benjamin R Nixon; Ariyoporn Thawornkaiwong; Janel Jin; Elizabeth A Brundage; Sean C Little; Jonathan P Davis; R John Solaro; Brandon J Biesiadecki
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

Review 3.  Structural based insights into the role of troponin in cardiac muscle pathophysiology.

Authors:  Monica X Li; Xu Wang; Brian D Sykes
Journal:  J Muscle Res Cell Motil       Date:  2005-02-09       Impact factor: 2.698

4.  Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-relaxation cycle in isolated cardiac myofibrils.

Authors:  M Kruger; S Zittrich; C Redwood; N Blaudeck; J James; J Robbins; G Pfitzer; R Stehle
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

5.  Combined troponin I Ser-150 and Ser-23/24 phosphorylation sustains thin filament Ca(2+) sensitivity and accelerates deactivation in an acidic environment.

Authors:  Benjamin R Nixon; Shane D Walton; Bo Zhang; Elizabeth A Brundage; Sean C Little; Mark T Ziolo; Jonathan P Davis; Brandon J Biesiadecki
Journal:  J Mol Cell Cardiol       Date:  2014-03-19       Impact factor: 5.000

6.  A preferred AMPK phosphorylation site adjacent to the inhibitory loop of cardiac and skeletal troponin I.

Authors:  Raquel Sancho Solis; Ying Ge; Jeffery W Walker
Journal:  Protein Sci       Date:  2011-04-08       Impact factor: 6.725

7.  Why does troponin I have so many phosphorylation sites? Fact and fancy.

Authors:  R John Solaro; Jolanda van der Velden
Journal:  J Mol Cell Cardiol       Date:  2010-02-25       Impact factor: 5.000

8.  Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction.

Authors:  Janet R Manning; Sarah O Perkins; Elizabeth A Sinclair; Xiaoqian Gao; Yu Zhang; Gilbert Newman; W Glen Pyle; Jo El J Schultz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-11       Impact factor: 4.733

9.  Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.

Authors:  Victoria N Parikh; Jing Liu; Ching Shang; Christopher Woods; Alex C Chang; Mingming Zhao; David N Charo; Zachary Grunwald; Yong Huang; Kinya Seo; Philip S Tsao; Daniel Bernstein; Pilar Ruiz-Lozano; Thomas Quertermous; Euan A Ashley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-05-18       Impact factor: 4.733

Review 10.  TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships.

Authors:  Juan-Juan Sheng; Jian-Ping Jin
Journal:  Gene       Date:  2015-10-23       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.